Success Metrics

Clinical Success Rate
76.9%

Based on 10 completed trials

Completion Rate
77%(10/13)
Active Trials
2(13%)
Results Posted
50%(5 trials)
Terminated
3(19%)

Phase Distribution

Ph not_applicable
5
31%
Ph phase_1
3
19%
Ph phase_2
5
31%

Phase Distribution

3

Early Stage

5

Mid Stage

0

Late Stage

Phase Distribution13 total trials
Phase 1Safety & dosage
3(23.1%)
Phase 2Efficacy & side effects
5(38.5%)
N/ANon-phased studies
5(38.5%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

71.4%

10 of 14 finished

Non-Completion Rate

28.6%

4 ended early

Currently Active

2

trials recruiting

Total Trials

16

all time

Status Distribution
Active(2)
Completed(10)
Terminated(4)

Detailed Status

Completed10
Terminated3
Recruiting2
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
16
Active
2
Success Rate
76.9%
Most Advanced
Phase 2

Trials by Phase

Phase 13 (23.1%)
Phase 25 (38.5%)
N/A5 (38.5%)

Trials by Status

completed1063%
terminated319%
withdrawn16%
recruiting213%

Recent Activity

Clinical Trials (16)

Showing 16 of 16 trials
NCT06409949Not Applicable

MitoQ Treatment of Claudication: Myofiber and Micro-vessel Pathology

Recruiting
NCT05229341Not Applicable

Evaluation of DNA Methylation Signatures for the Diagnosis and Management of Thyroid Nodules

Recruiting
NCT03212040Not Applicable

14 g vs. 16 g in Breast Biopsy

Completed
NCT00482755Phase 2

Sunitinib in Treating Patients With Newly Diagnosed Stage II or Stage III Breast Cancer That Can Be Removed by Surgery

Completed
NCT00665457Phase 2

Biomarkers in Women Receiving Chemotherapy & Celecoxib for Stage II or Stage III Breast Cancer Removable by Surgery

Terminated
NCT00700778Not Applicable

Recombinant Human Chorionic Gonadotropin in Preventing Breast Cancer in Premenopausal Women With BRCA1 Mutations

Terminated
NCT01259089Phase 1

Hsp90 Inhibitor AUY922 and Erlotinib Hydrochloride in Treating Patients With Stage IIIB-IV Non-Small Cell Lung Cancer

Completed
NCT00804245Phase 1

C-11 Choline PET-CT Scan in Finding Metastases in Patients With Newly Diagnosed High-Risk Prostate Cancer

Completed
NCT00194779Phase 2

Combination Chemotherapy and Filgrastim Before Surgery in Treating Patients With HER2-Positive Breast Cancer That Can Be Removed By Surgery

Completed
NCT00466752Phase 2

Sorafenib Tosylate and Gene Expression Analysis in Patients Undergoing Surgery For High-Risk Localized Prostate Cancer

Completed
NCT00813878

Nipple Secretion Samples in Detecting Breast Cancer in Patients and Healthy Participants Undergoing Breast Cancer Screening, Breast Diagnostic Studies, or Treatment for Benign Breast Disease

Terminated
NCT00362973

PET Scans in Assessing Response To Treatment in Patients Receiving Hormone Therapy or Trastuzumab for Breast Cancer

Completed
NCT00316823Not Applicable

Genetic Analysis in Diagnosing Thyroid Cancer in Patients With Thyroid Nodules

Completed
NCT00918788

Laser Spectroscopy of Breast Tissue Through a Needle Device

Completed
NCT00903214Phase 1

Riluzole in Women With Stage I, Stage II, or Stage IIIA Breast Cancer

Withdrawn
NCT00673569Phase 2

Laboratory Test in Predicting Response to Erlotinib in Patients With Relapsed Metastatic or Unresectable Non-Small Cell Lung Cancer That Did Not Respond to Previous Treatment

Completed

All 16 trials loaded

Drug Details

Intervention Type
PROCEDURE
Total Trials
16